News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Molecular Response (MRL) Announces Key Agreement in Translational Oncology with OncoMed Pharmaceuticals, Inc.



2/21/2012 8:03:56 AM

SAN DIEGO--(BUSINESS WIRE)--Molecular Response (MRL), a privately held molecular diagnostic services company and a leader in the identification of target populations for high value therapeutics, announced today an agreement with OncoMed Pharmaceuticals, Inc., significantly expanding the companies’ successful pilot program to develop unique patient-derived tumor xenografts (PDX), through the use of Molecular Response’s proprietary ‘living’ cell bank of primary tumor cells.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES